Injeksi Botulinum untuk Tatalaksana Overactive Bladder
DOI:
https://doi.org/10.55175/cdk.v45i5.785Keywords:
Injeksi BonT, overactive bladder, tatalaksanaAbstract
Overactive bladder (OAB) adalah kelainan yang berkaitan dengan gangguan berkemih, baik disertai inkontinensia maupun tidak, dibuktikan dengan tidak adanya infeksi atau kelainan patologis yang mendasari. OAB dapat mengenai semua usia dan sangat mengganggu kualitas hidup. Tatalaksana OAB meliputi terapi perilaku dan medikamentosa sebagai lini pertama, tetapi ketidakpatuhan dan efek samping sering menyebabkan kegagalan. Injeksi botulinum menghambat pelepasan neurotransmiter, sehingga dapat menurunkan kontraksi otot polos, dan dapat dipertimbangkan sebagai tatalaksana lini pertama.
Overactive bladder (OAB) is a urinary urgency, with or without urinary incontinence, without proven infection or other obvious pathology. OAB affects Ruality of life. The first-line treatment consists of combination of behavioural therapy and drugs, but failure is high due to side effects and noncompliance. Botulinum injection is an optional therapy that should be considered as a first line therapy. Its mechanism is to inhibit neurotransmitter release to reduce smooth muscle contractility.
Downloads
References
Drake MJ. Overactive bladder In: 8ein AJ, Kavoussi L, Partin A8, Peters CA, editors. Campbell-8alsh urology. 11th ed. Philadelphia: Elsevier. 2016 .p. 1796-805
Sakakibara R, Tateno F, Nagao T, :amamoto T, Uchiyama T, :amanishi T, et al. Bladder function of patients with Parkinsons disease. Int J Urol. 2014;21(7):638-46.
Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci :, Dolen I, Arslan U. The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J. 2014;25(11):1479-82.
Burkhard FC, Lucas M(, Berghmans LC, Bosch JLHR, Cruz F, Lemack (E, et al. EAU (uidelines on: Urinary incontinence in adults. EAU (uidelines on Urinary Incontinence 2016. ISBN 978-90-79754-98-4
(ormley E, Lightner D, Burgio K, Chai T, Clemens J, Culkin D, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6):2455-63.
Smith CP, Radziszewski P, Borkowski A, Somogyi (T, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64:871-5, discussion 875.
Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87:1044-9.
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: (enetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535-49.
Eldred-Evans D, Dasgupta P. Use of botulinum toxin for voiding dysfunction. Transl Androl Urol. 2017;6(2):234-51.
Knàpfer S, Schneider S, Averhoff M, Naumann C, Deuschl (, Jànemann K, et al. Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinsons disease. BMC Urol. 2016;16(1).
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200-35.
Jiang :, Liao C, Tang D, Kuo H. Efficacy and safety of intravesical OnabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS ONE. 2014;9(8):e105989.
Cui :, ;hou 9, ;ong H, :an H, ;hang :. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis. Neurourol Urodyn. 2015;34(5):413-9.
Cui :, 8ang L, Liu L, ;eng F, Niu J, 2i L, et al. Botulinum toxin-A injections for idiopathic overactive bladder: A systematic review and meta-analysis. Urol Int. 2013;91(4):429-38.
Chapple C, Sievert KD, MacDiarmid S, Khullar 7, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and Ruality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249-56.
Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome. Eur Urol. 2010;58(6):919-26.
Fowler CJ, Auerbach S, (insberg D, Hale D, Radziszewski P, Rechberger T, et al: OnabotulinumtoxinA improves health-related Ruality of life in patients with urinary incontinence due to idiopathic overactive bladder: A 36- week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62:148o57.
Denys P, Le Normand L, (hout I, Costa P, Chartier-Kastler E, (rise P, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: A multicentre, doubleblind, randomised, placebo-controlled doseranging study. Eur Urol. 2012;61:520o9
Kulaksizoglu H, Parman :. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsonss disease. Parkinsonism Relat Disord. 2010;16(8):531-4.
(ralÏn K, ElmÏr C, BrostrÚm E, Althin R, Malmberg L. Clinical practice of BOTO9¥ treatment for overactive bladder syndrome in Sweden: An assessment of resource use and external validity. Scand J Urol. 2017;5:1-5.
Brubaker L, (ousse A, Sand P, Thompson C, Patel 7, ;hou J, et al. Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J. 2012;23(8):1017-25.
Ambàhl D, Bedretdinova DA, Farag F, Lombardo R, Schneider MP. Urinary incontinence. EAU (uidelines . 2017 . Available from: https://uroweb.org/guideline/urinary-incontinence
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
